BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-14.73%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.16B
AUM Growth
+$5.16B
(-18%)
Cap. Flow
-$29M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
231
New
16
Increased
80
Reduced
52
Closed
17
Top Buys
| 1 |
Black Diamond Therapeutics
BDTX
|
$33.2M |
| 2 |
Fate Therapeutics
FATE
|
$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
$21.8M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$21.5M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$21M |
Top Sells
| 1 |
Teladoc Health
TDOC
|
$85.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
$49.3M |
| 3 |
Moderna
MRNA
|
$29.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$27.6M |
| 5 |
QuidelOrtho
QDEL
|
$21.9M |
Sector Composition
| 1 | Healthcare | 95.76% |
| 2 | Technology | 0.56% |
| 3 | Industrials | 0.54% |
| 4 | Communication Services | 0.17% |
| 5 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
126
DELISTED
CATALENT, INC.
CTLT
| $2.45M | 0.05% |
47,100
+12,800
| +37% | +$665K |
|
|
SYNH
127
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.44M | 0.05% |
61,900
+16,300
| +36% | +$643K |
|
128
Labcorp
LH
$22.8B
| $2.26M | 0.04% |
17,861
+12,335
| +223% | +$1.56M |
|
129
Sarepta Therapeutics
SRPT
$1.77B
| $1.96M | 0.04% |
20,000
+4,500
| +29% | +$440K |
|
|
XLRN
130
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.95M | 0.04% |
21,700
-2,500
| -10% | -$225K |
|
131
AbbVie
ABBV
$374B
| $1.94M | 0.04% |
25,400
-17,100
| -40% | -$1.3M |
|
|
MNTA
132
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.83M | 0.04% |
67,400
-95,000
| -58% | -$2.58M |
|
133
Acadia Pharmaceuticals
ACAD
$4.33B
| $1.78M | 0.03% |
42,000
+2,000
| +5% | +$84.5K |
|
134
uniQure
QURE
$933M
| $1.5M | 0.03% |
31,500
+2,600
| +9% | +$123K |
|
|
QTNT
135
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $1.41M | 0.03% |
355,899
| – | – |
|
136
Ascendis Pharma
ASND
$12.1B
| $1.34M | 0.03% |
+11,900
| New | +$1.34M |
|
137
Repligen
RGEN
$6.79B
| $1.31M | 0.03% |
13,600
| – | – |
|
138
FibroGen
FGEN
$49.3M
| $1.31M | 0.03% |
37,600
-900
| -2% | -$31.3K |
|
|
MRTX
139
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.22M | 0.02% |
15,900
-400
| -2% | -$30.7K |
|
140
Regenxbio
RGNX
$461M
| $1.2M | 0.02% |
36,900
+16,000
| +77% | +$518K |
|
141
Perrigo
PRGO
$3.23B
| $981K | 0.02% |
+20,400
| New | +$981K |
|
142
Ultragenyx Pharmaceutical
RARE
$3.09B
| $955K | 0.02% |
+21,500
| New | +$955K |
|
|
BLUE
143
DELISTED
bluebird bio
BLUE
| $910K | 0.02% |
19,800
+1,500
| +8% | +$68.9K |
|
|
BHVN
144
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $844K | 0.02% |
24,800
+2,100
| +9% | +$71.5K |
|
145
Apellis Pharmaceuticals
APLS
$3.56B
| $801K | 0.02% |
+29,900
| New | +$801K |
|
146
Coherus Oncology, Inc. Common Stock
CHRS
$138M
| $787K | 0.02% |
48,500
-100,000
| -67% | -$1.62M |
|
|
YI
147
111 Inc
YI
$53.3M
| $763K | 0.01% |
+115,429
| New | +$763K |
|
|
CLLS
148
Cellectis
CLLS
$260M
| $693K | 0.01% |
+75,300
| New | +$693K |
|
149
Zymeworks
ZYME
$1.06B
| $653K | 0.01% |
+18,400
| New | +$653K |
|
150
Domino's
DPZ
$15.9B
| $616K | 0.01% |
1,900
| – | – |
|